Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Medicinal chemistry of adenosine A3 receptor ligands.

Müller CE.

Curr Top Med Chem. 2003;3(4):445-62. Review.

PMID:
12570761
2.

A1 adenosine receptors and their ligands: overview and recent developments.

Müller CE.

Farmaco. 2001 Jan-Feb;56(1-2):77-80. Review.

PMID:
11347971
3.

Adenosine receptor ligands-recent developments part I. Agonists.

Muller CE.

Curr Med Chem. 2000 Dec;7(12):1269-88. Review.

PMID:
11032971
4.

2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors.

Ozola V, Thorand M, Diekmann M, Qurishi R, Schumacher B, Jacobson KA, Müller CE.

Bioorg Med Chem. 2003 Feb 6;11(3):347-56.

PMID:
12517430
5.

Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs.

Akkari R, Burbiel JC, Hockemeyer J, Müller CE.

Curr Top Med Chem. 2006;6(13):1375-99. Review.

PMID:
16918456
6.

Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.

Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA.

J Med Chem. 2002 Sep 26;45(20):4471-84.

PMID:
12238926
7.

[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.

Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Borea PA.

Mol Pharmacol. 2000 May;57(5):968-75.

8.

1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.

Hayallah AM, Sandoval-Ramírez J, Reith U, Schobert U, Preiss B, Schumacher B, Daly JW, Müller CE.

J Med Chem. 2002 Mar 28;45(7):1500-10.

PMID:
11906291
9.

Medicinal chemistry of adenosine A2A receptor agonists.

Cristalli G, Lambertucci C, Taffi S, Vittori S, Volpini R.

Curr Top Med Chem. 2003;3(4):387-401. Review.

PMID:
12570757
10.

A(3) adenosine receptor antagonists.

Müller CE.

Mini Rev Med Chem. 2001 Nov;1(4):417-27. Review.

PMID:
12369967
11.
12.

Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.

Alnouri MW, Jepards S, Casari A, Schiedel AC, Hinz S, Müller CE.

Purinergic Signal. 2015 Sep;11(3):389-407. doi: 10.1007/s11302-015-9460-9.

13.

Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.

Müller CE, Thorand M, Qurishi R, Diekmann M, Jacobson KA, Padgett WL, Daly JW.

J Med Chem. 2002 Aug 1;45(16):3440-50.

PMID:
12139454
14.

A3 receptor ligands: past, present and future trends.

Taliani S, Pugliesi I, Bellandi M, La Motta C, Da Settimo F.

Curr Top Med Chem. 2010;10(10):942-75. Review.

PMID:
20370658
15.
16.

Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors.

Varani K, Cacciari B, Baraldi PG, Dionisotti S, Ongini E, Borea PA.

Life Sci. 1998;63(5):PL 81-7.

PMID:
9714428
17.

A(3) adenosine receptor ligands: history and perspectives.

Baraldi PG, Cacciari B, Romagnoli R, Merighi S, Varani K, Borea PA, Spalluto G.

Med Res Rev. 2000 Mar;20(2):103-28. Review.

PMID:
10723024
18.

Adenosine receptors and their ligands.

Klotz KN.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91. Review.

PMID:
11111832
19.

Adenosine receptor agonists: from basic medicinal chemistry to clinical development.

Yan L, Burbiel JC, Maass A, Müller CE.

Expert Opin Emerg Drugs. 2003 Nov;8(2):537-76. Review.

PMID:
14662005
20.

Recent developments in adenosine A2A receptor ligands.

Cristalli G, Müller CE, Volpini R.

Handb Exp Pharmacol. 2009;(193):59-98. doi: 10.1007/978-3-540-89615-9_3. Review.

PMID:
19639279

Supplemental Content

Support Center